April 1st 2021
The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.
September 12th 2012
August 29th 2012
Investigational OAB agent shows significant improvements in phase III trial
April 21st 2005An agent under investigation for treatment of overactive bladder demonstrated statistically significant improvements over placebo in phase III trials, according to Schwarz Pharma, which is developing the drug, fesoterodine.
Some men may experience vision loss after taking PDE-5 inhibitor
April 8th 2005Within 36 hours after ingesting sildenafil citrate (Viagra) for erectile dysfunction, some men have nonarteritic anterior ischemic optic neuropathy (NAION), described as "stroke of the eye," according to a report of seven cases published in the Journal of Neuro-ophthalmology (2005; 25:9-13).
Two-drug combination shows positive results in men with ED
April 8th 2005A clinical study evaluating the effect of co-administration of an investigational intranasal agent PT-141 and sildenafil citrate (Viagra) shows positive results in patients with erectile dysfunction, according to researchers from Palatin Technologies Inc. and King Pharmaceuticals Inc.
Injectable LHRH agonist now available nationwide
April 8th 2005The FDA has approved triptorelin pamoate for injectable suspension (Trelstar Depot, 3.75 mg, and Trelstar LA 11.25 mg). The sustained-release, 1- and 3-month intramuscular injectable formulations are now available nationwide for the palliative treatment of advanced prostate cancer when orchiectomy or estrogen administration are either not indicated or are unacceptable to the patient.
Careful evaluation key in patients with refractory OAB
April 1st 2005Philadelphia--Urologists who manage patients with overactive bladder are challenged not only with choosing from a growing list of pharmacologic treatment options, but also with the prospect that some patients may not respond to oral anticholinergic treatment at all. In these patients with "refractory detrusor overactivity," it is important to realize that a number of factors mitigate against successful therapy, said Roger R. Dmochowski, MD, professor of urology at Vanderbilt University Medical Center, Nashville, TN.
Debate rages over Medicare coverage of sexual dysfunction drugs
April 1st 2005Washington--A controversy is brewing over whether Medicare should pay for erectile dysfunction drugs, which boiled over in the midst of heated discussions over the cost of the new Medicare drug benefit. Now estimated at $720 billion, the expected cost of the program is nearly double the government's original 2003 projections.
PVP laser found safe, efficacious in relieving LUTS
April 1st 2005Honolulu--Photoselective vaporization of the prostate (PVP) is a safe, efficacious approach to relieve lower urinary tract symptoms, according to a study presented at the annual Kimbrough Urological Seminar here. PVP engenders minimal morbidity while achieving significant cost savings, said study author Robert E. Reiter, MD.
Androgen deprivation temporarily reduces men's cognitive skills
March 18th 2005Men receiving androgen deprivation therapy for prostate cancer might notice a reduction in verbal fluency, visual recognition, and visual memory, according to a small trial published in the Feb. 28 online edition of Cancer.
PCPT analysis shows finasteride lengthens lives by preventing Ca
March 18th 2005If finasteride (Proscar) were prescribed prophylactically in older men, an estimated 316,760 years of life over 10 years would be saved through the prevention of prostate cancer, according to a new analysis of data from the Prostate Cancer Prevention Trial (PCPT).
NIH study to test antidepressant for interstitial cystitis
March 2nd 2005A new National Institutes of Health-funded study is recruiting adults newly diagnosed with either painful bladder syndrome or interstitial cystitis to determine if the antidepressant amitriptyline (Elavil) will reduce the pain and frequent urination associated with the conditions.
NIH study to test antidepressant for interstitial cystitis
March 2nd 2005A new National Institutes of Health-funded study is recruiting adults newly diagnosed with either painful bladder syndrome or interstitial cystitis to determine if the antidepressant amitriptyline (Elavil) will reduce the pain and frequent urination associated with the conditions.
Quinolone is more effective than amoxicillin-clavulanate for uncomplicated UTI
March 2nd 2005The fluoroquinolone ciprofloxacin (Cipro) appears to be more effective than amoxicillin-clavulanate (Augmentin) as a treatment for acute uncomplicated urinary tract infections in women, even in those infected with susceptible strains, according to a study published in last week's JAMA (2005; 293:949-55).
Investigational immunotherapy improves survival in men with advanced PCa
March 2nd 2005APC8015 (Provenge), an investigational form of immunotherapy, significantly improves survival in men with asymptomatic, metastatic androgen-independent prostate cancer compared with patients receiving placebo, according to a study being hailed as the first to show a survival benefit with a vaccine in patients with advanced prostate cancer.
FAQs about in-office injections: What you need to know
March 1st 2005A number of questions still surround coding and reimbursement for in-office drug injections. As a result, this article will take a slightly different approach, using a "frequently asked questions" format. I?ll repeat the questions I?ve been asked about the new drug payments at seminars and via phone and e-mail, and attempt to give you straight answers to the best of my understanding.
When and how to perform lap pyeloplasty for UPJ obstruction
March 1st 2005The ideal management strategy for correction of ureteropelvic junction (UPJ) obstruction remains undefined. Open pyeloplasty for correction of UPJ obstruction was first described by Anderson and Hynes over a century ago and remains the gold standard against which we must compare all alternative therapies.
Recurrent UTIs caused by original E coli strain
March 1st 2005Washington—A majority of recurrent urinary tract infections in women are caused by Escherichia coli bacterial persistence or reinfection with the originally infecting E coli strain, according to findings from a Danish study presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Resistant E coli shows 'huge' genetic variability
March 1st 2005Washington—Molecular typing reveals significant genetic variability among outpatient urinary isolates of fluoroquinolone-resistant Escherichia coli, according to a study of isolates in North America. DNA testing using pulsed-field gel electrophoresis (PGFE) showed no single fingerprint correlated with ciprofloxacin (Cipro) nonsusceptibility, the study's authors reported at the Interscience Conference on Anti-microbial Agents and Chemotherapy.
Some VUR patients can safely stop antibiotics
March 1st 2005San Francisco—Selected children with persistent vesicoureteral reflux can safely discontinue prophylactic antibiotics without a significant risk of upper tract infections or new renal scarring, according to results of a retrospective Canadian study.
Data find wide variation in BPH treatment patterns
March 1st 2005Mumbai, India—Rates of surgical and medical therapy for BPH at the county and state levels show significant systematic variation, according to Duke University researchers, who reported their findings during a presentation at the World Congress on Endourology here.
Healthy weight reduces risk of kidney stones
March 1st 2005Boston—Findings from analyses of data collected in three large, prospectively followed cohorts show that obesity and weight gain increase the risk of kidney stone formation in younger and older adult men and women, according to recently published research from Brigham and Women's Hospital, Harvard Medical School, Boston.